Calliditas Therapeutics
Stockholm
About Calliditas Therapeutics
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $210.4M
- Funding stage: M&A
- Last round: Post-IPO Debt (Dec 2023)
- Ticker: nasdaq:CALT
- Website: calliditas.se
- Phone: +46 8-411-3005
Industries & Categories
Biotechnology, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/calliditas-therapeutics-79703 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.